RxDoctor Payments Data

Hassan Ibrahim

Nephrology · Dallas, TXNPI 1538193008

Payments from drug & device makers

$16,970in general payments, 2019–2025

Across 41 payments — averaging $413.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Vifor Pharma, Inc.$7K
  • Veloxis Pharmaceuticals, Inc.$6K
  • Travere Therapeutics, Inc.$2K
  • Amgen$1K
  • Sanofi$145
  • One Lambda, Inc.$129
  • plus $137 from 3 others

What the payments were for

  • Consulting fees$9,32555%
  • Travel & lodging$5,45632%
  • Food & beverage$2,18913%

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,970 in reported general payments places this provider in the 80th percentile of 1,070 nephrology providers in Texas.

See all nephrology providers in Texas

Medicare billing

Part B allowed, 2024
$23,424
Medicare patients
95
Services billed
235

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide129$141,014
PromactaEltrombopag Olamine12$91,024
BiktarvyBictegrav/Emtricit/Tenofov Ala21$86,183
MounjaroTirzepatide61$71,821
JardianceEmpagliflozin57$67,597
Cinacalcet Hcl113$48,909
Valganciclovir Hcl152$47,439
EliquisApixaban44$37,197
Tresiba Flextouch U-100Insulin Degludec63$34,966
NulojixBelatacept13$32,017
Tresiba Flextouch U-200Insulin Degludec16$30,296
TrulicityDulaglutide20$28,664
CreonLipase/Protease/Amylase25$21,554
TradjentaLinagliptin20$20,950
ProcritEpoetin Alfa13$16,361

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$88$141,014129 claims
Johnson & JohnsonProcrit$25$16,36113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,070 nephrology providers in Texas.

Other nephrology in Dallas

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →